A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Janssen Research & Development, LLC
600 participants
Mar 5, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate how well nipocalimab works as compared to placebo in participants with moderate to severe Systemic lupus erythematosus (SLE, a long-term disease where the immune system mistakenly attacks its own healthy tissues, causing swelling and redness in various organs).
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Nipocalimab will be administered.
Placebo will be administered.
Protocol-defined topical and systemic standard of care background treatments.
Locations(222)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07438496